Hard To Treat Diseases, Incorporated Announces: Details of Patent Application Relating to Cancer
Tuesday May 9, 8:00 am ET
DELRAY BEACH, FLORIDA--(MARKET WIRE)--May 9, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces the Company's patent application relating to cancer is the second of two patent applications that the Company filed, owns and controls.
In December 2005, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Cancer. This application provides a novel method for inhibition and prevention of cancer, to the diseases associated with such cancers and to the therapeutic treatment of diseases or disorders caused by such cancers. This application will became a utility patent application in December 2006.
HTTD's patent applications are the result of testing conducted on two substances; Tubercin (T-5) and Specific Substance of Maruyama ("SSM"). Please refer to the Company's press release dated May 2, 2006 titled "Details of Patent Application Relating to Viral Infections" for additional information on these substances.
Tubercin (T-5), SSM or a functional derivative thereof can be used for treatment, as stated in the abstracts of HTTD's patent applications. SSM is the substance that the Company will be presenting to pharmaceutical companies for acquisition regarding HTTD's applications. Regardless of whether HTTD acquires marketing rights to Tubercin (T-5), HTTD solely owns and controls utility patent rights to the drug.
The Company is aggressively moving forward and advancing its position with the rights owned that are unencumbered, as opposed to waiting to secure rights that may be unnecessary.
The above application is one of two patent applications currently being packaged for presentation to major drug companies. Pharmaceutical companies that specialize in oncology and infectious diseases are the targeted candidates for the acquisition of HTTD's patent rights, testing and research. Protocols for additional testing that potentially may lead to new patent applications for the treatment of other diseases are included in the presentation to drug companies.
Additional information is available on the Company's website at: www.htdsotc.com and a presentation regarding HTTD by Mr. King is available at the following link: publiccoreport.net |
